Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year
You may also be interested in...
No Cease-Fire: India Seeks $190 Million Tax From Sanofi’s Shantha Deal
India’s tax department has filed a petition with the Supreme Court, challenging an earlier judgment that sided with Sanofi in a tax dispute that could impact future acquisitions in the country.
No Cease Fire: India Seeks $190 Million Tax From Sanofi’s Shantha Deal
India’s tax department has filed a petition with the Supreme Court, challenging an earlier judgment that sided with Sanofi in a tax dispute that could impact future acquisitions in the country.
Will The Vodafone Win Against India’s Income Tax Department Benefit Sanofi In Shantha Deal?
India Supreme Court ruling in Vodafone case may set precedent for offshore acquisitions, but Sanofi-Shantha deal has key differences.